Delayed Graft Function Clinical Trial
Official title:
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Verified date | February 2017 |
Source | Opsona Therapeutics Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
When a patient receives a kidney transplant particularly if the kidney is from an older
donor or one who has had the kidney removed after their heart has stopped, there is a risk
that the newly transplanted kidney may not function immediately. If the delay in function
means that dialysis is needed in the first 7 days after the transplantation then this is
known as delayed graft function or dDGF. Also delayed graft function that does not require
dialysis but is present because the serum creatinine does not fall sufficiently is known as
functional delayed graft function or fDGF. This problem is often due to an excessive
inflammatory reaction to not having had a blood supply between the time of donation and
transplant.
OPN-305 is a monoclonal antibody that blocks Toll-like Receptor 2 which is thought to be
partly responsible for increasing the risk of this inflammation. It is hoped that the
effects of the inflammation will be reduced and therefore prevent dDGF and fDGF from
occurring.
The purpose of the study is to explore how effective OPN-305 is in preventing dDGF and fDGF
as well as improving other measures of kidney function and the overall safety of the
antibody. In the first part of the study, each patient received an Infusion of one of three
possible doses of OPN-305 or a placebo and in the second part the most suitable dose of
OPN-305 and a placebo would be used. The purpose of this second part of the study is to find
out if a dose of OPN-305 which has already been tested in an earlier part of this study can
prevent kidney graft dysfunction. For the purposes of this study, kidney function will be
assessed using the composite of delayed graft function (dDGF) because dialysis is necessary
in the first 7 days and functional delayed graft function that does not require dialysis but
is present because the serum creatinine, a key measure of renal function, does not fall
sufficiently (fDGF) in the first 7 days post-transplant.
Protocol OPN305-103 follows out to 12 months post-transplant the clinical status and graft
function of patients who have completed the 6-month post-transplant period under Part A or
Part B of OPN305-102.
Status | Completed |
Enrollment | 252 |
Est. completion date | June 30, 2016 |
Est. primary completion date | June 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria INCLUSION CRITERIA FOR TRANSPLANT RECIPIENTS - First or second renal transplant recipient - for second renal transplantations; - The second transplant should NOT be due to rejection - Panel Reactive Antibody (PRA) should be <10% - Minimum 3 months since the loss of the first transplanted kidney - Dialysis-dependent at the time of transplantation as documented by: - Requirement for at least 2 dialysis sessions/week in the 56 days before transplantation INCLUSION CRITERIA FOR DONOR KIDNEY: - The donor kidney must be considered compatible according to local transplant guidelines - An ECD donor defined as: o Extended Criteria Donor defined as: - Donor =60 years of age - Donor 50-59 years of age with two of three of the following criteria present: - Death due to cerebrovascular accident - Pre-existing history of systemic hypertension - Terminal creatinine > 1.5mg/dL (132.6 µmol/L) - Kidney allograft maintained in cold storage with or without machine perfusion Exclusion Criteria EXCLUSION CRITERIA FOR TRANSPLANT RECIPIENTS: - Use of an investigational drug in the 30 days before Study Day 1 - Participation in any other research - Known hypersensitivity to human monoclonal antibodies or any of the study-drug excipients - Previous hypersensitivity to basiliximab or anti-thymocyte globulin (ATG) - History or known HIV, HBV, or HCV-positive - History of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin or cervical intraepithelial neoplasia - Scheduled to undergo multi-organ transplantation - Planned dual kidney transplantation - Presence of clinically significant infections requiring continued therapy - Active tuberculosis - Existence of any surgical or medical condition, other than the current transplantation which, in the opinion of the investigator, might significantly alter the distribution, metabolism or excretion of study medication - Presence of uncontrolled diabetes mellitus. - Current drug and/or alcohol abuse - History or presence of a medical condition or disease that in the investigator's assessment would place the patient at an unacceptable risk for study participation - Lactating or pregnant woman - Patient institutionalized by administrative or court order EXCLUSION CRITERIA FOR ALL DONOR KIDNEYS - DCD or SCD donor kidney - Terminal creatinine >3mg/dL - Donor who is known to have received an investigational drug for I-R injury or graft rejection (immunosuppressant) in the 48h before organ recovery - Participation in any other research (drug or non-drug) - Kidney donor <5 years of age or <20kg body weight - Living donor allograft - HLA or ABO incompatible kidney as defined by a negative cytotoxic crossmatch - Donor institutionalized by administrative or court order |
Country | Name | City | State |
---|---|---|---|
Austria | Research Site | Linz | |
Belgium | Research Site | Brussels | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Leuven | |
Belgium | Research Site | Liege | |
Czech Republic | Research Site | Praha | |
France | Research Site | Bordeaux | |
France | Research Site | Paris | |
France | Research Site | Toulouse | |
Germany | Research Site | Berlin | |
Germany | Research Site | Berlin | |
Germany | Research Site | Bochum | |
Germany | Research Site | Bonn | |
Germany | Research Site | Erlangen | |
Germany | Research Site | Heidelberg | |
Germany | Research Site | Koln | |
Germany | Research Site | Mannheim | |
Germany | Research Site | Munster | |
Germany | Research Site | Tubingen | |
Netherlands | Research Site | Groningen | |
Netherlands | Research Site | Leiden | |
Netherlands | Research Site | Nijmegen | |
Netherlands | Research Site | Rotterdam | |
Poland | Research Site | Bydgoszcz | |
Poland | Research Site | Lodz | |
Poland | Research Site | Szczecin | |
Poland | Research Site | Warsaw | |
Poland | Research Site | Warszawa | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Madrid | |
Spain | Research Site | Santander | |
Switzerland | Research Site | Zurich | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Newcastle upon Tyne | |
United States | Research Site | Bronx | New York |
United States | Research Site | Charleston | South Carolina |
United States | Research Site | Chicago | Illinois |
United States | Research Site | Dallas | Texas |
United States | Research Site | Fort Worth | Texas |
United States | Research Site | Harrisburg | Pennsylvania |
United States | Research Site | Livingston | New Jersey |
United States | Research Site | Los Angeles | California |
United States | Research Site | New Orleans | Louisiana |
United States | Research Site | New Orleans | Louisiana |
United States | Research Site | New York | New York |
United States | Research Site | Richmond | Virginia |
United States | Research Site | Tampa | Florida |
United States | Research Site | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Opsona Therapeutics Ltd. |
United States, Austria, Belgium, Czech Republic, France, Germany, Netherlands, Poland, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure of Early Graft Function EGF | Initiation of dialysis in the first 7 days following renal transplantation and failure of serum creatinine to decrease by at least 10% daily on 3 successive days during the first week post transplantation | First 7 days following renal transplantation | |
Secondary | Creatinine at 7 and 14 days and at 1, 3 and 6 months | Measure of creatinine at 7 and 14 days and at 1, 3 and 6 months | 7 and 14 days and at 1, 3 and 6 months | |
Secondary | Cystatin C at 7 and 14 days and at 1, 3 and 6 months | Measure of Cystatin C at 7 and 14 days and at 1, 3 and 6 months | 7 and 14 days and at 1, 3 and 6 months | |
Secondary | Symmetrical dimethylarginine at 7 and 14 days and at 1, 3 and 6 months | Measure of symmetrical dimethylarginine at 7 and 14 days and at 1, 3 and 6 months | 7 and 14 days and at 1, 3 and 6 months | |
Secondary | Incidence of slow graft function | Slow graft function to be assessed over first 5 days post-transplant | 5 days post-transplant | |
Secondary | Serum creatinine over time | Measure of Serum creatinine over time | over the duration of follow-up | |
Secondary | Composite endpoint | Components of the composite endpoint are: Incidence of biopsy-proven kidney allograft rejection (biopsies will be done on a for-cause basis only) Graft loss Reports of patient death(s) Patients lost to follow-up |
6 months | |
Secondary | Time to biopsy-proven kidney allograft rejection | Time to biopsy-proven kidney allograft rejection | 6 months | |
Secondary | Time to first dialysis or functional delayed graft function and delayed graft function duration | Duration of DGF is defined as either: Time from transplantation to time of completion of final dialysis for DGF Time from transplantation to time when creatinine starts to fall by at least 10% without dialysis |
30 days | |
Secondary | Blood and urine biomarkers for acute kidney injury (AKI) | Serum NGAL, urinary NGAL, a-GST, p-GST, KIM-1 and IL-18 | days 2, 7, 14, 28, 90 and 180 | |
Secondary | Duration of initial hospitalization | Duration of initial hospitalization | 6 months | |
Secondary | Duration of subsequent readmissions | Duration of subsequent readmissions | 6 months | |
Secondary | Reason for subsequent readmissions | Reason for subsequent readmissions | 6 months | |
Secondary | Number of Adverse events (AEs) | Number of Adverse events (AEs) | 6 months | |
Secondary | Nature of Adverse events (AEs) | Nature of Adverse events (AEs) | 6 months | |
Secondary | Incidence of infections | Incidence of infections by category and organism | 6 months | |
Secondary | Rate of primary non-function (permanent lack of function of the allograft) | 6 months | ||
Secondary | Number of dialysis sessions between 0 and 30 days post-transplantation | Number of dialysis sessions between 0 and 30 days post-transplantation | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02312115 -
Delayed Renal Allograft Function and Furosemide Treatment
|
Phase 2 | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02346968 -
Evaluation of CAF22 After Renal Transplantation
|
||
Completed |
NCT00298181 -
YSPSL for Prevention of Delayed Graft Function Part A
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05166460 -
Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation
|
N/A | |
Recruiting |
NCT03071536 -
Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT05513807 -
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant
|
Phase 3 | |
Recruiting |
NCT04005469 -
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
Active, not recruiting |
NCT02474667 -
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
|
Phase 3 | |
No longer available |
NCT02026934 -
CliniMACS® CD34+ Reagent System for Expanded Access Use
|
N/A | |
Terminated |
NCT00217152 -
A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors
|
Phase 4 | |
Recruiting |
NCT05430620 -
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
|
Phase 3 | |
Completed |
NCT03864926 -
Envarsus in Delayed Graft Function (E-DGF)
|
Phase 4 | |
Recruiting |
NCT06367205 -
Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations
|
N/A | |
Completed |
NCT02610296 -
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
|
Phase 3 | |
Active, not recruiting |
NCT02568696 -
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
|
||
Recruiting |
NCT01837043 -
Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
|
Phase 2 | |
Terminated |
NCT01878786 -
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01395719 -
Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function
|
N/A |